Objective: Identify echocardiographic parameters at p4 day postnatal that predict the subsequent need for closure of a clinically significant patent ductus arteriosus (sPDA) in extremely-low-birth-weight neonates (ELBW).
Introduction
The ductus arteriosus (DA) has a prominent role in cardiovascular adaptation during fetal development, shunting oxygenated blood away from the pulmonary circulation to the systemic vasculature. In term neonates and preterm neonates >1500 g birth weight (BW), the DA spontaneously closes within 96 h after birth in >95% of neonates. 1 In contrast, it remains patent in a substantial population of very low BW (BW p1500 g) neonates. 2, 3 In these neonates, the incidence of a persistent patent DA (PDA) increases with decreasing estimated gestational age (EGA) and BW, [2] [3] [4] [5] although not all studies have arrived at this conclusion. 6 As a group, as many as 31% of very low BW neonates develop a clinically and hemodynamically significant PDA (sPDA) with signs of increased left to right shunting, pulmonary edema and an enlarged cardiothymic shadow on chest X-ray. 7 The presence of a sPDA in very low BW preterm neonates has been associated with pulmonary edema and hemorrhage, prolonged mechanical ventilation and oxygen requirement, development of bronchopulmonary dysplasia (BPD) or chronic lung disease, necrotizing enterocolitis, intracranial hemorrhage and retinopathy of prematurity. 8 Therefore, it is generally believed that early closure of a PDA in very low BW neonates may prevent these morbidities, resulting in aggressive closure of the PDA either medically or by surgical ligation by many physicians. However, Laughon et al. 9 have suggested after a detailed review of DA closure and outcomes that prevention and/or treatment of a PDA have not decreased the associated morbidities, suggesting aggressive closure should not be a standard of care.
In a recent study of extremely low BW neonates (ELBW; BW<1000 g), we 10 observed spontaneous closure of the DA in 34% of neonates within the first week after birth. This was developmentally regulated, DA closure increasing with advancing gestation. It should be noted that the closure was unrelated to BW. This suggested that early aggressive treatment of the PDA in ELBW neonates needed to be reassessed, as spontaneous closure of the DA occurs in at least a third of these neonates by 7 day postnatal. Further, results from recent trials of the routine use of prophylactic indomethacin have raised additional uncertainty about aggressive closure. For example, in the TIPP trial, prophylactic indomethacin did not improve survival and/or neurodevelopmental outcome. 11 Furthermore, neonates receiving prophylactic indomethacin for DA closure did not demonstrate a decreased rate of BPD when compared with those receiving placebo and in whom the DA closed spontaneously. 9, 12 Finally, indomethacin usage is not without potential adverse side effects. 13 Therefore, it is necessary to better characterize and define the ELBW population at-risk for developing an sPDA rather than to treat all ELBW neonates indiscriminately. To accomplish this, it is essential to develop a method that will accurately predict which ELBW neonates, if any, might benefit from early intervention. In this study, we sought to identify specific early echocardiographic (ECHO) parameters that would stratify ELBW neonates at risk of development of an sPDA and predict the need for subsequent treatment and closure of a PDA. 10 Briefly, the study population consisted of preterm ELBW neonates without congenital heart disease who survived during the first 10 day of life. Exclusion criteria included neonates who received comfort care because of extreme prematurity (p24 weeks EGA) as determined from the obstetrical dates or the Ballard examination when this was questionable or differed from the obstetric estimate by >2 weeks, 14, 15 congenital anomalies, including congenital heart disease, or in whom ECHO or EGA data were missing. The study was approved by the University of Texas Southwestern Medical Center Institutional Review Board for Human Research and Parkland Memorial Hospital.
Methods

Subjects
Protocol
After obtaining informed consent, neonates underwent a complete diagnostic ECHO within 4 days after birth to document cardiac anatomy and patency of the DA. Focused ECHO examinations were subsequently carried out every other day until 10 day postnatal to evaluate DA patency. If a PDA was not seen or closure was documented before 10 day postnatal, serial examinations were stopped, and a final ECHO was carried out at 10 day to confirm persistent DA closure. Results of these studies were not available to the team responsible for the care of enrolled neonates. However, in the presence of clinical indications, the clinicians could request results of studies carried out within the previous 24 h. Clinical care, including the need for treatment of an sPDA, was determined by the patient care team and not influenced by the results of the study ECHO. Prophylactic ductal closure with indomethacin is not used in our institution. The need for closure was determined by comprehensive evaluation of clinical signs of an sPDA (for example, tachycardia >165 b.p.m. at rest, bounding pulses, an increase in pulse pressure >20 mm Hg and presence of a PDA murmur), radiographic evidence of a significant left-to-right shunt with cardiomegaly and increased shunt vasculature, and an ECHO confirming a large PDA with a left-to-right shunt. 2, 3, 10, 16 For neonates on ventilatory support, the inability to wean from the ventilator in the presence of an sPDA as defined and a significant left-to-right ductal shunt was also used as an indication for DA closure. The presence of a large PDA by ECHO in the absence of clinical signs was not the basis for treatment and closure. In the presence of an sPDA, indomethacin was administered at a dose of 0.2 mg kg À1 every 12 h for three doses. Contraindications to indomethacin therapy included serum creatinine >1.2 mg 100 ml À1 , urine output <1.0 ml kg -1 h
À1
in the preceding 8 h, platelet count <60 000 mm À3 , or evidence of active bleeding and necrotizing enterocolitis. In the presence of an sPDA, neonates with contraindications to indomethacin or those who failed to respond to indomethacin underwent surgical ligation.
ECHO measurements
In this study, each ECHO was reviewed by one of the authors (CR) without knowledge of the final outcome (that is, spontaneous closure, indomethacin therapy or surgical ligation) or other clinical variables. Flow across the DA was described as aorta-topulmonary artery (PA) only or bidirectional. Exclusive flow from PA to aorta was not encountered. The presence or absence of diastolic flow in the central branch pulmonary arteries was noted. Left atrial:aortic root ratio dimension was measured from the parasternal long axis view. Shortening fraction was measured with standard M-mode methods. 17 Following the description by Wald, 18 the size of the PDA, if present, was defined as small, moderate or large on the basis of the ratio of the smallest ductal diameter to the ostium of the left PA (PDA:LPA ratio). A ratio X1 defined a large PDA, X0.5 but <1 a moderate PDA, and <0.5 a small PDA.
Data analysis
Using a multiple logistic regression model, we analyzed the prediction of the treatment of sPDA using: (1) size of the PDA, (2) flow pattern in the PDA and branch pulmonary arteries, (3) left atrial:aortic root ratio and (4) shortening fraction. Previous analyses of this population showed that spontaneous closure of PDA was more commonly associated with greater EGA. 10 Therefore, in a separate model, EGA and initial size of the PDA were examined for their ability to predict subsequent treatment of an sPDA. EGA was measured in weeks and dichotomized as <27 weeks or X27 weeks. This was determined from the data of Koch et al., 10 which show an increased likelihood of spontaneous DA closure in neonates X27 weeks EGA, >60-80% vs p40%. Size of the PDA was dichotomized using the PDA:LPA ratio scored as closed or small, and moderate or large. The Omnibus test and Hosmer Lemeshow test were used to assess model goodness of fit and calibration. Data are presented as the mean ± s.d. unless otherwise noted. T-tests were used for group comparisons of continuous level data, and statistical testing of dichotomous variables was performed using Fisher's exact test (SPSS, Version 15).
Results
Complete ECHO data were available for analysis in 115 of the 122 neonates included in the original study. 10 Their demographics, initial medical care and diagnoses in the first 48 h are described in Table 1 . The population was predominantly Hispanic (>60%), mirroring the delivery population at Parkland Memorial Hospital. Eighty-one (70%) were <27 weeks gestation and 34 (30%) X27 weeks. The mean age at the time of the initial ECHO was 2.6 ± 0.7 days, and 96% of neonates had one ECHO by day 3 of life ( Table 2 ). In all, 33 (29%) had a closed DA on the initial ECHO, whereas the DA was small in 21 (18%), moderate in 9 (8%) and large in 52 (45%). It is to be noted that of the 11 neonates with an ECHO on day 1, 73% had similar readings at 3-4 day postnatal, and PDA size determined on an ECHO performed in the first 2 days postnatal did not differ on a repeat ECHO carried out 2 days later. It is important to note that none of the neonates who subsequently developed an sPDA were considered to have met the criteria for treatment by the clinical care team within 3 days after the initial ECHO at an age of 6.2±0.7 days.
A total of 47 (41%) of the 115 neonates with complete ECHO data did not receive treatment for an sPDA (Table 3) , 62 (54%) received a course of intravenous indomethacin and 6 (5%) underwent a primary ductal ligation for medical indications. The results of their ECHO at p4 days are described in Table 3 . The neonates that underwent primary ligation are included in the treatment group. At the time of the first ECHO, 79% of untreated neonates required some form of ventilatory support vs 90% of the treated neonates (P>0.1). Although the number of neonates requiring ventilatory support fell in both groups with advancing postnatal age, there were no differences in the number remaining on support (P>0.1), for example, 55 vs 61% at 7 days and 53 vs 58% at 10 days, respectively. In all, 22 (35%) of the neonates that received indomethacin did not demonstrate PDA closure and subsequently underwent surgical ligation. A total of 13 neonates had a small or closed DA on the initial ECHO and eventually required treatment.
Multiple logistic regression modeling, using variables of PDA size (PDA:LPA ratio), flow pattern in the PDA and branch PAs and the left atrial:aortic ratio, showed statistical significance only for PDA size estimated by the PDA:LPA ratio (P ¼ 0.01: odds ratio 4.0; 95% confidence interval: 1.4-9.5). A separate model was constructed using independent variables EGA and PDA size on the initial ECHO to predict need for treatment. The Omnibus test for overall model Goodness of Fit was highly significant, P<0.001, whereas the Hosmer Lemeshow test was not (P ¼ 0.57), indicating adequate model fit and calibration. Based on probabilities determined by our model, 79% of cases were correctly classified as needing or not needing treatment for an sPDA. The odds ratio for requiring treatment for a sPDA based on clinical, radiographic and ECHO data in neonates with a moderate or large PDA by ECHO in the first 4 days of life was 15 times greater than for neonates with a small or closed PDA on the initial ECHO after controlling for EGA (odds ratio 15.4; 95% confidence interval: 5.9-41.7). For neonates X27 weeks gestation, the odds for requiring treatment for a sPDA were reduced 77% (95% confidence interval: 38.9-92.8%) after Table 4 . Because of the effect of EGA on sPDA, we carried out a subgroup analysis, dividing neonates into groups with a gestational age either above or below 27 weeks to determine the sensitivity, specificity, positive predictive value and negative predictive value (Table 5) . It is important to note that the sensitivity for the <27 week group was 80% with a specificity of 86% and positive predictive value of 92%. Although the sensitivity and specificity in the older group were reasonable, the negative predictive value was 85%. We also carried out a bivariate sub-group analysis to determine whether there was an association between initial PDA size and the success or failure of indomethacin treatment (that is, requiring surgical ligation after indomethacin, n ¼ 59). We excluded neonates who underwent primary surgical ligation because of contraindications to indomethacin therapy. Although there was no significant relationship (P ¼ 0.1), 85% of neonates with a closed or small PDA on the initial ECHO were successfully treated with indomethacin after developing an sPDA, whereas only 57% with moderate or large PDA on the initial ECHO were successfully closed with indomethacin.
Discussion
The ELBW neonate has an increasing risk of a sPDA with decreasing EGA, ranging from B25% at >29 weeks to B85% at <25 weeks. 10 This has resulted in the use of prophylactic closure of the PDA in many institutions to prevent perceived morbidity secondary to the development of an sPDA. Recently, Koch et al.
10
reported that up to a third of these neonates undergo spontaneous closure if untreated; however, early identification of this population
is not yet possible. In this study, we observed that the size of the PDA, determined by the PDA:LPA ratio obtained on an ECHO carried out in the first 4 days of life, predicted with good sensitivity those ELBW neonates who would develop a sPDA and ultimately require closure. It is to be noted that an ECHO carried out at 3-4 days predicted the development of an sPDA 2-3 days before distinct clinical signs were evident and treatment was provided. Furthermore, neonates with a moderate or large PDA at this time were 15 times more likely to require treatment for a sPDA than those with a small or no PDA on the initial ECHO. Estimated gestational age was also observed to be useful in predicting the need for treatment of an sPDA and risk stratification. This is consistent with earlier reports that an older EGA correlates with an increase in the spontaneous closure of the DA.
2-5, 10 We did not examine the effect of BW as in our earlier analysis of this population of ELBW neonates it did not correlate with the closure or patency because of inclusion of older more mature growth restricted neonates. 10 In this report, a moderate to large PDA, defined by the PDA:LPA ratio on an ECHO obtained at p4 day postnatal in neonates <27 weeks EGA (neonates 15 times more likely to require ductal closure), had very good sensitivity, specificity and positive predictive value (91%) for the subsequent need for closure of a sPDA. Conversely, a negative initial ECHO in neonates X27 weeks EGA had a negative predictive value of 85%, indicating a decreased likelihood of developing a sPDA. It is important to note that the PDA:LPA ratio prediction appears independent of the need for sustained ventilator support as this did not differ between the untreated and treated neonates at 4, 7 and 10 days postnatal. Thus, the use of PDA:LPA ratio could be used to identify and facilitate the treatment of a select population of ELBW neonates destined to develop a sPDA or to design a clinical trial of prophylactic closure in the at-risk population. However, the present observations should be prospectively confirmed beforehand. 19 we did not identify a significant relationship between PDA size and the response to indomethacin. Whereas the study was not powered to examine this, it is notable that there was an association between an initially small PDA or closed DA and subsequent successful closure with indomethacin. Further studies to clarify this question should be considered.
It is important to recognize the limitations of this study. Although the data were prospectively collected, the retrospective nature of the ECHO evaluations requires that a prospective study be designed to validate the logistic model. For the same reason, we were unable to quantify ECHO measurements such as ejection fraction (a more accurate quantification of left ventricular function), peak velocity across the DA, measurement of mitral inflow E:A ratio, diastolic reversal in the aorta and left ventricular output. In addition, the ECHO measurements were made by a single observer; therefore, we cannot comment on either the inter-observer variability or reproducibility of these results. Although the diagnosis of an sPDA was based on criteria agreed upon by clinicians involved in patient care, the subjectivity in decision making was still present, creating difficulties in controlling the end point for treatment vs no treatment. It is our belief, nonetheless, that our results reflect our current clinical practice and are of significant practical value.
We believe that the results of this study may be useful for patient care in several ways. First, we have identified a time point for the application of echocardiography to guide clinical decision-making that coincides with the median age for ductal closure in the subset of ELBW preterm neonates that will eventually develop spontaneous permanent closure of the PDA. Second, the size of the PDA, as determined by the PDA:LPA ratio in the first 4 days of life has a strong predictive ability to identify neonates at risk of developing a sPDA that will require closure, excluding neonates not in need of treatment. 9 Risk stratification of this population using this approach may allow clinicians to develop a simple protocol for imaging and early intervention. Finally, by treating only the highest risk neonates at an early time point, complications from prophylactic treatment are minimized and therapeutic efficacy optimized. Whereas the role of a PDA in the development of morbidities of prematurity is still under debate, the use of early diagnosis, such as that described in this report, may permit the design of future trials that will provide additional information about the risk-to-benefit analysis of prophylactic intervention and identify the subset of high-risk neonates that should be included in future prospective studies.
